Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694325 | 0.89 | FGFR2 (0.40) | METCYP3A4ACP1YES1 | |
| SCHEMBL2210862 | 0.87 | KDR (0.38) | METCYP3A4KCNH2ACP1YES1 | |
| SCHEMBL3698351 | 0.81 | PIK3CA (0.41) | METACP1YES1 | |
| SCHEMBL3704091 | 0.80 | YES1 (0.48) | METCYP3A4YES1 | |
| SCHEMBL2209662 | 0.79 | YES1 (0.44) | METCYP3A4KCNH2YES1 | |
| SCHEMBL2210697 | 0.77 | PIK3CA (0.36) | METCYP3A4ACP1YES1 | |
| SCHEMBL2210176 | 0.77 | YES1 (0.42) | METCYP3A4ACP1YES1 | |
| SCHEMBL2206413 | 0.76 | FGFR2 (0.39) | METCYP3A4KCNH2YES1 | |
| SCHEMBL3705744 | 0.75 | MET (0.45) | METCYP3A4KCNH2YES1 | |
| SCHEMBL3707561 | 0.74 | MAPKAPK2 (0.55) | ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | MET 567/4885CYP3A4 3294/4885KCNH2 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.